H. Herfarth / B.G. Feagan / U.R. Fölsch / J. Schölmerich / M.H. Vatn / M. Zeitz (Hgg.)

Targets of Treatment in Chronic Inflammatory Bowel Diseases

Herausgegeben:Herfarth, H.; Feagan, B. G.; Fölsch, U. R.

• Gebundenes Buch

Produktbeschreibung

The first gene responsible for Crohn's disease has now been identified and the pathophysiological understanding of inflammatory bowel disease as well as its practical treatment have made much progress in recent years. Thus it is obviously important to consider the targets and the aims of treatment in context.
The Falk Symposium No. 131 (Part II of the Gastroenterology Week Freiburg 2002), held in October 2002 in Freiburg, Germany, in its first part was dedicated to newly defined and partly alternative therapeutic targets. In addition, an attempt was made to learn from experts from other fields such as pneumology or dermatology. The second part was dedicated to the aims of treatment in daily practice. Aside from general treatment, aims such as amelioration of symptoms, pre-conditions of treatment, the view of the patients, and aspects of life quality were dealt with.
This volume is the proceedings of the symposium and is important reading for both clinicians and basic scientists.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Falk Symposium 131
• Verlag: Springer / Springer Netherlands
• Artikelnr. des Verlages: 978-0-7923-8784-8
• 2003
• Seitenzahl: 272
• Erscheinungstermin: 31. Juli 2003
• Englisch
• Abmessung: 241mm x 160mm x 20mm
• Gewicht: 558g
• ISBN-13: 9780792387848
• ISBN-10: 0792387848
• Artikelnr.: 22440878

Inhaltsangabe

List of principle authors. Preface. Defining Targets of Treatment by
Analysis of Gut Inflammation. 1. State of the Art Lecture: Theories of IBD
aetiology from the 1930s to the 1960s; D.B. Sachar. I: Defining Targets by
Understanding Aetiopathogenesis of Gut Inflammation. 2. Development of
novel drugs for IBD based on molecular targets; S. Schreiber. 3. On the
role of innate immunity during mucosal defence and intestinal infections:
Are there new therapeutic targets for intervention? S. Bauer. 4. Enteric
bacteria: Innocent bystanders, therapeutic targets or vehicles for mucosal
delivery of therapeutic molecules? R.B. Sartor. II: Tools for Therapeutic
Development. 5. Do animal models always give the right direction for
therapy? C.O. Elson, et al. 6. Are cell lines and cultures a good way to
develop therapeutic approaches? G. Rogler. 7. Characterization of
intestinal barrier function: A putative target for therapeutical
modification; M. Gehring, J.-D. Schulzke. III: Alternative Concepts New
Targets in the Making. 8. The adipose tissue as a source of proinflammatory
signals in Crohn's disease? J.-F. Colombel, et al. 9. Intraluminal targets
in Crohn's disease: The possible role of bile acids; A.F. Hofmann. 10.
Therapeutic targets in rheumatoid arthritis: Is there a lesson to be
learned for gastroenterologists? U. Müller-Ladner. V: General Targets. 11.
Interstitial lung diseases and inflammatory bowel diseases:
Pathophysiological parallels and differences; J. Müller-Quernheim. 12. A
functional genomics approach to study wound repair: The roles of activin
and S100A8/S100A9 in the healing process; I.S. Thorey, et al. 13.
Neuroendocrine-immune interactions: A novel therapeutic approach? S.M.
Collins. Aims of Treatment in Daily Practice. 14. State of the Art Lecture:
Evolution of treatment from the 1930s to the end of the 1980s; P. Riis.
15. Extraintestinal manifestations Important target of treatment or just an
expression of disease activity? F. Tavarela-Veloso. 16. What do patients
want? Defining treatment goals from the other side; J. Minchew. 17.
Measuring health-related quality of life: Fad, fantasy or fruitful
exercise? E.J. Irvine. VI: Specific Targets. 18. Specific targets Diarrhea;
W. Kruis, et al. 19. Abdominal pain as a therapeutic target in inflammatory
bowel disease; H.J.F. Hodgson. 20. Strictures in IBD Are there differential
indications for surgery or endoscopic dilation? G.van Assche, et al. 21.
Spectrum of inflammatory bowel diseases related arthropathy: are there
differential treatment options? M.de Vos. VII: Special Problems. 22.
Magnetic resonance imaging (MRI) in patients with IBD: A new method to
assess disease activity; S. Feuerbach, et al. 23. Cancer prevention in
inflammatory bowel disease as a treatment goal; A. Ekbom. VIII: Quality of
Care. 24. The impact of age and social environment on therapeutic concepts;
C. Gasché. 25. Avoiding side effects: A therapeutic goal? W.J. Sandborn.
Index.